Sanara MedTech Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 delivered 19% revenue growth and a return to GAAP net profitability, driven by strong sales of core surgical products and expanded market presence. Guidance for 2026 was reaffirmed, with continued investment in sales and R&D supporting long-term growth.
-
The company has transitioned to a pure-play surgical wound care focus, achieving strong revenue growth and expanding its reach to over 4,000 facilities. With three core technologies and a robust commercial strategy, it projects continued double-digit growth, stable margins, and new product launches through 2027.
Fiscal Year 2025
-
Record 2025 revenue of $103.1M (up 19% YoY) and 93% gross margin reflect strong execution and focus on surgical markets. 2026 guidance projects 13–17% revenue growth, with new Vizient contract and clinical evidence supporting further expansion.
-
Q3 2025 saw 22% revenue growth, margin expansion, and strong operating leverage, driven by core surgical products. THP operations were discontinued to focus on the surgical segment, with continued investment in product innovation and commercial expansion.
-
Leadership transition and expanded management position the company for future growth. Strong Q2 results were driven by balanced performance in soft tissue and bone repair, with significant upside in contracted facilities and a robust product pipeline, including OsStic expected in 2027.
-
Q2 2025 saw 28% revenue growth, improved profitability, and strong cash flow, led by the surgical segment. Strategic alternatives are being explored for THP, with reduced investment planned. The company remains focused on growth, innovation, and capital preservation.
-
Q1 2025 saw 26% revenue growth, strong gross margin, and expanded distribution, but net loss widened due to higher expenses and investments in new technology. Sanara Surgical drove growth, while Tissue Health Plus advanced its tech platform and pilot program.
Fiscal Year 2024
-
Net revenue grew 33% to $86.7M in 2024, with strong gains in soft tissue products and positive Adjusted EBITDA. The company expanded its commercial reach, advanced its THP segment for a 2025 pilot, and secured new financing, while continuing to invest in growth initiatives.
-
Significant growth driven by innovative wound care platforms, expanding hospital penetration, and a strong sales network. Evidence-based outcomes support adoption, while a new value-based care model targets the large post-acute wound market. Q3 revenue hit a record $21.7 million.
-
Q3 2024 saw 35% year-over-year revenue growth to $21.7M and improved adjusted EBITDA, though net loss widened due to higher SG&A and interest expenses. The surgical segment delivered positive EBITDA, while THP investments continued ahead of a mid-2025 launch.
-
Q2 2024 revenue rose 28% year-over-year to $20.2 million, with record sales in soft tissue products and positive Adjusted EBITDA despite a net loss. Strategic investments continue in both surgical and post-acute wound care, with a major THP launch planned for 2025.
-
The meeting covered director elections, governance amendments, incentive plan approval, and auditor ratification. All proposals passed by majority or plurality vote, and no shareholder questions were raised.